stoxline Quote Chart Rank Option Currency Glossary
  
Elevai Labs, Inc. Common Stock (ELAB)
1.8597  0.11 (6.27%)    02-06 11:45
Open: 1.8
High: 1.87
Volume: 219,660
  
Pre. Close: 1.75
Low: 1.7498
Market Cap: 6(M)
Technical analysis
2025-02-06 11:18:30 AM
Short term     
Mid term     
Targets 6-month :  3.65 1-year :  4.75
Resists First :  3.13 Second :  4.07
Pivot price 1.97
Supports First :  1.61 Second :  1.33
MAs MA(5) :  1.74 MA(20) :  2.01
MA(100) :  11.04 MA(250) :  73.22
MACD MACD :  -0.4 Signal :  -0.4
%K %D K(14,3) :  5.9 D(3) :  5.3
RSI RSI(14): 39.8
52-week High :  176 Low :  1.61
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ELAB ] has closed above bottom band by 36.0%. Bollinger Bands are 91.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 52 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.79 - 1.8 1.8 - 1.8
Low: 1.67 - 1.68 1.68 - 1.69
Close: 1.74 - 1.75 1.75 - 1.76
Company Description

Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.

Headline News

Tue, 28 Jan 2025
Univest Securities, LLC Announces Closing of $1.92 Million Warrant Inducement for its Client PMGC Holdings Inc. (NASDAQ: ELAB) - The Manila Times

Thu, 02 Jan 2025
Carmell Announces Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair Care Products - Yahoo Finance

Wed, 27 Nov 2024
Elevai Labs announces 1-for-200 reverse stock split - Investing.com

Fri, 22 Nov 2024
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess - GlobeNewswire

Fri, 22 Nov 2024
Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance - GlobeNewswire

Mon, 04 Nov 2024
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 3 (M)
Shares Float 16 (M)
Held by Insiders 72.9 (%)
Held by Institutions 18.2 (%)
Shares Short 9,420 (K)
Shares Short P.Month 686 (K)
Stock Financials
EPS -88.92
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.21
Profit Margin -192.1 %
Operating Margin -231.6 %
Return on Assets (ttm) -88.6 %
Return on Equity (ttm) -351 %
Qtrly Rev. Growth 91.3 %
Gross Profit (p.s.) 0.55
Sales Per Share 0.8
EBITDA (p.s.) -1.56
Qtrly Earnings Growth 0 %
Operating Cash Flow -6 (M)
Levered Free Cash Flow -4 (M)
Stock Valuations
PE Ratio -0.03
PEG Ratio 0
Price to Book value 8.09
Price to Sales 2.21
Price to Cash Flow -0.91
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android